CRT-0066101 free base · Synonyms: CRT 0066101 · CRT0066101

CRT0066101 is a potent and orally active PKD inhibitor.

For research use only. Not for human or veterinary use.

Target PKD Pim Apoptosis

Research area Inflammation/Immunology Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

CRT-0066101 structure

CAS No.: 956123-34-5

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 460.00	BP-02133-25mg	In stock	Get quote
50 mg	USD 720.00	BP-02133-50mg	In stock	Get quote
100 mg	USD 1,160.00	BP-02133-100mg	In stock	Get quote
250 mg	USD 2,300.00	BP-02133-250mg	In stock	Get quote
500 mg	USD 3,700.00	BP-02133-500mg	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Related forms

BP-02133A — CRT0066101 dihydrochloride

Description

CRT0066101 is a potent and orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively . CRT0066101 is also a potent PIM2 inhibitor with an IC50 of ~135.7 nM. CRT0066101 exhibits anti-inflammatory activity in mice LPS -induced lung injury models, and has anticancer effects .

Biological activity

In Vitro CRT0066101 (5 µM; 1 h) blockS both the basal and NT-induced pS916-PKD1/2 (activated PKD1/2) in Panc-1 and Panc-28 cells. CRT0066101 abrogates NT-induced phosphorylation of Hsp27 (pS82-Hsp27), attenuates PKD1-mediated NF-κB activation, and abrogates expression of NF-κB-dependent-dependent proliferative and pro-survival proteins. CRT0066101 significantly inhibits Panc-1 cell proliferation, with an IC50 value of 1 µM. CRT0066101 results in a 6-10 fold induction of apoptosis in Panc-1 cells. CRT0066101 significantly reduces cell proliferation of Colo357, Panc-1, MiaPaCa-2, and AsPC-1 cells but had a modest effect in Capan-2 cells. In Vivo CRT0066101 (80 mg/kg/day; oral gavage; once daily; for 21 days) in Panc-1 orthotopic model potently blocks tumor growth in vivo. CRT0066101 (10 mg/kg, i.p., every two days for 3 times) exhibits a protective effect against LPS-induced pneumonia and alleviates lung damage in C57BL/6J mice.

Identifiers

SMILES: N[C@H](CC)CNC1=NC(C2=C(O)C=CC(C3=CN(C)N=C3)=C2)=NC=C1
InChIKey: SCJXQZZYGYLKJG-CQSZACIVSA-N

Specifications

MW (average): 338.4069
Formula: C₁₈H₂₂N₆O
CAS No.: 956123-34-5
Physical state: Solid
Color: White to light yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 3 years; 4℃ 2 years; In solvent -20℃ 1 month;

Solubility

soluble in DMSO

Documents

References

[1]. Harikumar KB, et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2010 May;9(5):1136-46.

[2]. Xi Chen, et al. Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy-based virtual screening and machine learning evaluation. Arch Pharm (Weinheim). 2024 Jan 23:e2300516.

[3]. Cui B, et al., Small molecule inhibitor CRT0066101 inhibits cytokine storm syndrome in a mouse model of lung injury. Int Immunopharmacol. 2023 Jul;120:110240.

Same target

Search PKD

Same research area

Search Inflammation/Immunology